2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Daniel P. Petrylak, MD, discusses the utilization of enfortumab vedotin-ejfv in patients with muscle-invasive bladder cancer (MIBC).
Daniel P. Petrylak, MD, professor of medicine and urology, coleader, Cancer Signaling Networks, Yale Cancer Center, discusses the utilization of enfortumab vedotin-ejfv (Padcev) in patients with muscle-invasive bladder cancer (MIBC).
The phase 1b/2 EV-103 trial (NCT03288545) investigated the use of enfortumab vedotin alone and in various combinations in patients with urothelial cancer. Cohort H featured patients with MIBC who were eligible for surgical resection but ineligible for cisplatin-based chemotherapy. These patients received 3 cycles of neoadjuvant enfortumab vedotin on days 1 and 8 of every 3-week cycle.
Preliminary analysis of this cohort showed that of the 22 patients enrolled, 36.4% achieved a pathologic complete response with no viable tumor present in the specimen cystectomy, Petrylak says. Moreover, 50% of patients experienced a reduction in tumor size, Petrylak explains.
Overall, enfortumab vedotin seems to have significant efficacy in this patient population, Petrylak concludes.